[
  {
    "ts": null,
    "headline": "COO vs. WST: Which Stock Is the Better Value Option?",
    "summary": "COO vs. WST: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=56d74088b611213461faa8878f2c7b1d576953f5c7f7642090495a79b3c75b16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771000802,
      "headline": "COO vs. WST: Which Stock Is the Better Value Option?",
      "id": 139086827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "COO vs. WST: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=56d74088b611213461faa8878f2c7b1d576953f5c7f7642090495a79b3c75b16"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Lowers Price Target to $265",
    "summary": "Barclays  analyst Luke Sergott   maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and lowers the price target from $325 to $265.",
    "url": "https://finnhub.io/api/news?id=d394424f40d8391d1b032d3090391616191cd156ca619712da046f780d9bea2d",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770990793,
      "headline": "Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Lowers Price Target to $265",
      "id": 139096418,
      "image": "",
      "related": "WST",
      "source": "Benzinga",
      "summary": "Barclays  analyst Luke Sergott   maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and lowers the price target from $325 to $265.",
      "url": "https://finnhub.io/api/news?id=d394424f40d8391d1b032d3090391616191cd156ca619712da046f780d9bea2d"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical Services Q4 Earnings Call Highlights",
    "summary": "West Pharmaceutical Services (NYSE:WST) said it ended 2025 with fourth-quarter results above its own expectations, citing strong demand for high-value product (HVP) components, continued progress on Annex 1-driven upgrades, and ongoing growth tied to GLP-1 therapies. Management also introduced initi",
    "url": "https://finnhub.io/api/news?id=635385bf2386df4847607bda3f541aafcf016323833fe0d277a23be244b5c493",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770984796,
      "headline": "West Pharmaceutical Services Q4 Earnings Call Highlights",
      "id": 139081569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services (NYSE:WST) said it ended 2025 with fourth-quarter results above its own expectations, citing strong demand for high-value product (HVP) components, continued progress on Annex 1-driven upgrades, and ongoing growth tied to GLP-1 therapies. Management also introduced initi",
      "url": "https://finnhub.io/api/news?id=635385bf2386df4847607bda3f541aafcf016323833fe0d277a23be244b5c493"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook",
    "summary": "In the past week, West Pharmaceutical Services reported its 2025 results, with full-year sales rising to US$3.07 billion and net income edging up to US$493.7 million, while also issuing 2026 guidance that calls for first-quarter net sales of US$770 million to US$790 million and full-year net sales of US$3.22 billion to US$3.28 billion, including a foreign-exchange benefit. An important detail in that outlook is that organic net sales growth is expected to outpace reported growth,...",
    "url": "https://finnhub.io/api/news?id=be6c484e53a70478fd31bcab3aa3d4c620728c6e01e0d194e4d05b2f1ef68068",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770942175,
      "headline": "West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook",
      "id": 139077104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "In the past week, West Pharmaceutical Services reported its 2025 results, with full-year sales rising to US$3.07 billion and net income edging up to US$493.7 million, while also issuing 2026 guidance that calls for first-quarter net sales of US$770 million to US$790 million and full-year net sales of US$3.22 billion to US$3.28 billion, including a foreign-exchange benefit. An important detail in that outlook is that organic net sales growth is expected to outpace reported growth,...",
      "url": "https://finnhub.io/api/news?id=be6c484e53a70478fd31bcab3aa3d4c620728c6e01e0d194e4d05b2f1ef68068"
    }
  }
]